Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 24Myelodysplastic Syndromes 5Leukemia, Biphenotypic, Acute 5Leukemia, Myelomonocytic, Chronic 3Neoplasm, Residual 2Lung Neoplasms 2Liver Neoplasms 2Leukemia 2Carcinoma, Hepatocellular 2Blast Crisis 2Sarcoma, Myeloid 1Recurrence 1Neoplasms by Histologic Type 1Myeloproliferative Disorders 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hematologic Neoplasms 1Down Syndrome 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1Anemia, Refractory, with Excess of Blasts 1

Interventions

atezolizumab 3fludarabine 2entrectinib 2cobimetinib 2capmatinib 2alectinib 2Vemurafenib 2Pemetrexed 2Nivolumab 2Cisplatin 2spartalizumab 1repotrectinib 1pertuzumab 1lutetium Lu 177 dotatate 1gilteritinib 1enzalutamide 1durvalumab 1copper dotatate CU-64 1cemiplimab 1Trastuzumab 1Sodium Chloride 1Radiotherapy 1Radiosurgery 1Mitomycin 1Lutetium-177 1Lutetium 1Injections 1Idarubicin 1HuMax-IL8 1Granulocyte Colony-Stimulating Factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Neoplasms by Histologic Type × Idarubicin × Clear all
NCT06001788 2026-04-14

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Kura Oncology, Inc.

Phase 1 Recruiting
171 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Neoplasms by Histologic Type, Leukemia, Myeloid, Acute, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡